TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 07, 2005Vol.31 No.36
TCL Archive John Niederhuber named NCI chief operating officer; the surgeon was asked to leave two previous positions. October 07, 2005Vol.31 No.36
TCL Archive Cancer death rate dropping 1.1 percent a year, annual report finds. October 07, 2005Vol.31 No.36
TCL Archive White House appoints NCI Director Andrew von Eschenbach acting FDA commissioner after Lester Crawford resigns. September 30, 2005Vol.31 No.35
TCL Archive ASCO Backs Sentinel Node Biopsy In Some Early Stage Breast Cancer September 30, 2005Vol.28 No.9
TCL Archive Von Eschenbach says he will continue as NCI director and give both jobs “100 percent.” September 30, 2005Vol.31 No.35
TCL Archive Breast Cancers Detected By Mammograms Have Better Prognosis, Trials Analysis Finds September 30, 2005Vol.28 No.9
TCL Archive Legal experts say too many conflicts involved. HHS gave von Eschenbach a waiver for his role in C-Change. September 30, 2005Vol.31 No.35
